SS
ATHE

SBI Securities’s Alterity Therapeutics ATHE Stock Holding History

SBI Securities’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$4 – 4031
2025
Q3 		$4 Buy
+1
New +$5 ﹤0.01% 4113

Other funds holding ATHE

TLCM
Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SBI Securities's ATHE Position: Q4 2025 in Review

SBI Securities sold out of Alterity Therapeutics (ATHE) in Q4 2025, closing a stake of 1 share — an estimated $4 sold.

SBI Securities first reported a position in ATHE in Q3 2025 and held it in 1 quarter. The position peaked at $4 in Q3 2025. 18 funds tracked by Wall St. Rank hold ATHE as of Q4 2025.

  • SBI Securities reported no remaining Alterity Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SBI Securities sold 1 Alterity Therapeutics share in Q4 2025, an estimated $4.
  • SBI Securities first reported a position in Alterity Therapeutics in Q3 2025 and held it in 1 quarter.
  • SBI Securities's Alterity Therapeutics position peaked at $4 in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q4 2025.

Based on SBI Securities's 13F filing for Q4 2025, filed 3 Feb 2026.